Appointment of Sir Gregory Winter as Interim Chair of Biosceptre's Board of Directors

CAMBRIDGE, U.K. - Dec. 14, 2016 - PRLog -- Biosceptre is pleased to announce the appointment of Sir Gregory Winter as Chair of the Biosceptre Board of Directors. Sir Gregory has led the Scientific Advisory Board of Biosceptre for over 4 years and joined the Board of Directors as a non-executive director in May 2016.

Sir Gregory said: "My interest in Biosceptre began when Domantis was involved in developing a domain antibody against nfP2X₇ – a promising new target for immuno-oncology. Having served on the Biosceptre Scientific Advisory Board for some years and on the Board of Directors for a short time, I am pleased to take the role of Chair of the Board of Directors as the Biosceptre programme advances towards clinical trials."

Gavin Currie, CEO of Biosceptre, said, "We are delighted that Sir Gregory has taken this further role at Biosceptre, increasing again his leadership and support for the business. I also take this opportunity to thank the outgoing Chair, Peter Newton, for his long support and service to Biosceptre."

About Sir Gregory Winter:

Sir Gregory Winter is Master of Trinity College Cambridge, and until recently was a member of the Medical Research Council's Laboratory of Molecular Biology (LMB), serving as both a Head of Division and as Deputy (and Acting) Director.

Sir Gregory developed technology for making humanised antibodies and human antibodies in bacteria. Many of the therapeutic antibodies on the market now were developed using methods devised by Sir Gregory. As a Founder and Director of Cambridge Antibody Technology (acquired by AstraZeneca), of Domantis (acquired by GSK) and currently of Bicycle Therapeutics Limited, he has unique biotechnology industry experience.

Sir Gregory was elected a Fellow of the Royal Society (FRS) in 1990 and awarded the Royal Medal by the society in 2011 "for his pioneering work in protein engineering and therapeutic monoclonal antibodies, and his contributions as an inventor and entrepreneur". Sir Gregory has also won several international awards including the King Faisal International Prize for Medicine, the Cancer Research Institute William B. Coley Award and the Canada Gairdner International Award. Sir Gregory was appointed Knight Bachelor in 2004.

About Biosceptre:

Biosceptre is a Cambridge, UK headquartered biotechnology company focused on developing next generation cancer treatments targeting nfP2X_7. Biosceptre's product pipeline includes systemic antibody-based therapeutics and vaccines, to treat a range of cancer types, as well as a topical product for skin cancers. With the phase I trial of the topical product now completed, Biosceptre will be seeking potential partners for development and licensing, and will re-enter the clinic in 2017.

Biosceptre will be in attendance at the Biotech Showcase 2017 in San Francisco from 9^th to 12^th January.